Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exelixis Makes The Case For Early Filing Of Cabozantinib In Frontline Kidney Cancer

Executive Summary

Company recruited clinical experts to explain why Phase II CABOSUN should be enough for approval and why a Phase III study is now impractical.

You may also be interested in...



Takeda Adds Exelixis Arrow To Oncology Quiver

Takeda's acquisition of Japanese rights to Exelixis' lead product fills a gap in the oncology portfolio while adding another piece to the US company's global licensing jigsaw.

Exelixis' Strong Cabometyx Start Signals Changing Of Guard In Kidney Cancer Market

One of a trio of new drugs shaking up the kidney cancer market, Cabometyx (cabozantinib) does better than expected in its first nine weeks on the US market, and additional indications are on the near horizon.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS119303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel